These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34420059)

  • 1. Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.
    Cho H; Ryu MH; Lee HE; Kim HD; Kang YK
    Cancer Immunol Immunother; 2022 Apr; 71(4):829-838. PubMed ID: 34420059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
    Li Q; Lv M; Jiang H; Wang Y; Yu S; Li W; Yu Y; Liu T
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):287-295. PubMed ID: 31667572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
    Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
    J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
    Ryu MH; Yoo C; Kim JG; Ryoo BY; Park YS; Park SR; Han HS; Chung IJ; Song EK; Lee KH; Kang SY; Kang YK
    Eur J Cancer; 2015 Mar; 51(4):482-488. PubMed ID: 25661103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
    Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
    Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
    Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.
    Li Q; Jiang H; Li H; Xu R; Shen L; Yu Y; Wang Y; Cui Y; Li W; Yu S; Liu T
    Oncotarget; 2016 Aug; 7(31):50656-50665. PubMed ID: 27409420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer.
    Horita Y; Nishino M; Sugimoto S; Kida A; Mizukami A; Yano M; Arihara F; Matsuda K; Matsuda M; Sakai A
    Anticancer Drugs; 2019 Jan; 30(1):98-104. PubMed ID: 30124494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
    Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
    Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
    Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
    Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
    Makiyama A; Sukawa Y; Kashiwada T; Kawada J; Hosokawa A; Horie Y; Tsuji A; Moriwaki T; Tanioka H; Shinozaki K; Uchino K; Yasui H; Tsukuda H; Nishikawa K; Ishida H; Yamanaka T; Yamazaki K; Hironaka S; Esaki T; Boku N; Hyodo I; Muro K
    J Clin Oncol; 2020 Jun; 38(17):1919-1927. PubMed ID: 32208960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
    Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
    Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
    Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; Matsusaka S; Segawa Y; Nakamura M; Sasaki K; Nagao N; Hatachi Y; Yuasa Y; Asami S; Takeuchi M; Furukawa H; Nakajima T;
    Gastric Cancer; 2018 May; 21(3):421-427. PubMed ID: 28936560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group.
    Gürbüz M; Akkuş E; Sakin A; Urvay S; Demiray AG; Şahin S; Şakalar T; Erol C; Şendur MAN; Şahin AB; Çubukçu E; Güven DC; Kılıçkap S; Ergün Y; Uncu D; Turhal NS; Üskent N; Çınkır HY; Demir A; Acar R; Karadurmuş N; Türker S; Altınbaş M; Karaoğlan M; Şenler FÇ
    J Gastrointest Cancer; 2022 Jun; 53(2):282-288. PubMed ID: 33538958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
    Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
    Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.
    Oudard S; Culine S; Vano Y; Goldwasser F; Théodore C; Nguyen T; Voog E; Banu E; Vieillefond A; Priou F; Deplanque G; Gravis G; Ravaud A; Vannetzel JM; Machiels JP; Muracciole X; Pichon MF; Bay JO; Elaidi R; Teghom C; Radvanyi F; Beuzeboc P
    Eur J Cancer; 2015 Jan; 51(1):45-54. PubMed ID: 25459391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.
    Zhu B; Wu JR; Zhou XP
    Medicine (Baltimore); 2015 Aug; 94(34):e1428. PubMed ID: 26313797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
    Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
    Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.